Overview

A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE - Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. - Radiotherapy may cause adverse effect such as xerostomia and mucositis. - Amifostine has the ability of protecting the normal tissue but also has some side effects. PURPOSE - This phase II trial is to study the protecting effect and safety of different Amifostine regimens in patients with nasopharyngeal carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Dalian Merro Pharmaceutical Co. Ltd
Treatments:
Amifostine